Treats infection caused by various strains of influenza A virus. ANDA 75819, held by PharmoBedient. Amantadine Hydrochloride.
As of Nov 21, 2026, ANDA 75819 (Amantadine Hydrochloride), held by PharmoBedient, was first approved by FDA on Sep 11, 2002, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Amantadine hydrochloride oral solution USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2002 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Amantadine Hydrochloride50MG/5ML · syrup;oral | Amantadine Hydrochloride | Discontinued |
| Jul 10, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 17, 2012 | Supplement 2Labeling | Approved | None posted |
| Jan 10, 2012 | Supplement 1Labeling | Approved | None posted |
| Sep 11, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters